Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced the promotion of Thomas Englese to chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will continue to lead sales, marketing, market access, and commercial operations for the company's key products, including TONMYA for fibromyalgia and the acute migraine treatments Zembrace SymTouch and Tosymra.
The promotion comes at a pivotal time for Tonix as it works to broaden the launch of TONMYA, which was approved by the U.S. Food and Drug Administration as the first new treatment for fibromyalgia in more than 15 years. President and CEO Seth Lederman emphasized Englese's instrumental role in building Tonix's commercial organization and launching TONMYA. Englese expressed the company's focus on expanding access, growing its patient and prescriber base, and increasing sales as it broadens the TONMYA launch.
Tonix's commercial infrastructure supports its CNS portfolio, which includes TONMYA and its migraine products. The company is also advancing research to maximize the science behind TONMYA through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. Additionally, the CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In the immunology space, Tonix is progressing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The promotion of Englese signals Tonix's commitment to strengthening its commercial capabilities as it seeks to establish a foothold in the fibromyalgia market and maximize the potential of its product portfolio. With TONMYA being the first new fibromyalgia treatment in over a decade, the company's commercial leadership will be critical in driving market adoption and patient access. The expansion of the TONMYA launch is expected to be a key driver of revenue growth for Tonix in the near term.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. For more information, visit the company's newsroom at https://ibn.fm/TNXP.
